A 24-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 186 and 372 μg of OPN-375 Twice a Day (BID) in Subjects With Chronic Sinusitis With or Without the Presence of Nasal Polyps
Phase of Trial: Phase III
Latest Information Update: 21 Feb 2019
At a glance
- Drugs Fluticasone propionate (Primary)
- Indications Sinusitis
- Focus Therapeutic Use
- Sponsors OptiNose
- 10 Dec 2018 According to an OptiNose media release, first patient has been enrolled in the trial.
- 10 Dec 2018 Status changed from planning to recruiting, according to an OptiNose media release.
- 19 Mar 2018 New trial record